Immutrin
PrivateLast Round
Series A
Mar 24, 2026
Total Funding Raised
$87M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Immutrin is a biotechnology company that develops antibody therapies designed to deplete systemic amyloid deposits and reverse amyloidosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immutrin Comparables
Compare Immutrin with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Attralus | 80% | |
| AstraZeneca | 74% | |
| Prothena Corporation plc | 74% |
Immutrin Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 24, 2026 |
Key People
Founding team and executive leadership
Immutrin Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cambridge Enterprise Ventures | Series A |
| Frazier Life Sciences | Series A |
| Cambridge Enterprise | Series A |
| Cambridge Innovation Capital | Series A |
| F-Prime Capital | Series A |
| Qiming Venture Partners | Series A |
| SR One | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 16, 2026
Grew 58% QoQ from 12 to 19 employees.
- Jul 17, 2026
Grew 45% QoQ, from 11 to 16 employees.
Immutrin Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Immutrin's valuation, stock price, and market status.
Is Immutrin a public or private company?
Immutrin is a private company.
What is the current stock price of Immutrin?
Immutrin is a private company with no public stock price. No recent secondary market data is available.
How much is Immutrin worth (valuation)?
Valuation information for Immutrin is not publicly available.
Can I buy Immutrin stock?
Immutrin shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Immutrin's last funding round?
Immutrin's most recent funding round was Series A on March 24, 2026.
Who are the main investors in Immutrin?
Key investors in Immutrin include Frazier Life Sciences.
Will Immutrin IPO soon?
No public IPO plans have been announced for Immutrin.
How can I track Immutrin secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Immutrin's secondary market activity and sign up for updates.